Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Net Income (2020 - 2025)

GeneDx Holdings has reported Net Income over the past 6 years, most recently at -$17.7 million for Q4 2025.

  • Quarterly results put Net Income at -$17.7 million for Q4 2025, down 424.86% from a year ago — trailing twelve months through Dec 2025 was -$21.0 million (up 59.89% YoY), and the annual figure for FY2025 was -$21.0 million, up 59.8%.
  • Net Income for Q4 2025 was -$17.7 million at GeneDx Holdings, down from -$7.6 million in the prior quarter.
  • Over the last five years, Net Income for WGSWW hit a ceiling of $32.7 million in Q3 2021 and a floor of -$308.7 million in Q4 2022.
  • Median Net Income over the past 5 years was -$34.7 million (2021), compared with a mean of -$52.2 million.
  • Biggest five-year swings in Net Income: skyrocketed 157.81% in 2021 and later plummeted 668.24% in 2022.
  • GeneDx Holdings' Net Income stood at -$40.2 million in 2021, then plummeted by 668.24% to -$308.7 million in 2022, then skyrocketed by 91.65% to -$25.8 million in 2023, then soared by 121.09% to $5.4 million in 2024, then plummeted by 424.86% to -$17.7 million in 2025.
  • The last three reported values for Net Income were -$17.7 million (Q4 2025), -$7.6 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.